4-[(2-Benzyloxyphenyl)hydroxymethyl]-benzoic Acid Methyl Ester | 433331-26-1

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: 4-[(2-Benzyloxyphenyl)hydroxymethyl]-benzoic Acid Methyl Ester
• 英文别名: methyl 4-[(2-benzyloxyphenyl)hydroxymethyl]benzoate；methyl 4-[hydroxy-(2-phenylmethoxyphenyl)methyl]benzoate
• CAS: 433331-26-1
• 化学式: C₂₂H₂₀O₄
• 分子量: 348.398
• InChiKey: CDIQGKSSRWGQRX-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  4
• 重原子数：
  26
• 可旋转键数：
  7
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.14
• 拓扑面积：
  55.8
• 氢给体数：
  1
• 氢受体数：
  4

反应信息

• 作为反应物：
  描述：

  4-[(2-Benzyloxyphenyl)hydroxymethyl]-benzoic Acid Methyl Ester 在 palladium-carbon 氢气 作用下， 以 乙醇 为溶剂， 反应 18.0h， 以to give methyl 4-(2-hydroxybenzyl)benzoate (1.7 g)的产率得到methyl 4-(2-hydroxybenzyl)benzoate
  参考文献：
  名称：

  Glucopyranosyloxybenzylbenzene derivatives, medicinal compositions containing the same and intermediates in the production thereof

  摘要：

  本发明涉及由通式表示的葡萄糖吡喃氧基苯甲基苯类衍生物： 其中，R1表示氢原子、羟基、取代或未取代氨基、氨基甲酰基、取代或未取代（较低烷基）基团、取代或未取代（较低烷氧基）基团等；R2表示氢原子或较低烷基基团；R3表示取代或未取代（较低烷基）基团、取代或未取代（较低烷氧基）基团、取代或未取代（较低烷硫基）基团等，或其药学上可接受的盐，其具有对人类SGLT2的抑制活性，并且可用作预防或治疗与高血糖有关的疾病，如糖尿病、糖尿病并发症或肥胖症的药物，包括其制剂和中间体。

  公开号：

  US20050059614A1
• 作为产物：
  描述：

  2-苄氧基溴苯 在 盐酸 、 magnesium 作用下， 以 四氢呋喃 为溶剂， 反应 1.0h， 生成 4-[(2-Benzyloxyphenyl)hydroxymethyl]-benzoic Acid Methyl Ester
  参考文献：
  名称：

  GLUCOPYRANOSYLOXYBENZYLBENZENE DERIVATIVES AND MEDICINAL USE THEREOF

  摘要：

  公开号：

  EP1367060B1

文献信息

• Glucopyranosyloxybenzylbenzene derivatives, medicinal compositions containing the same and intermediates in the production thereof
  申请人：Fujikura Hideki

  公开号：US20050113315A1

  公开（公告）日：2005-05-26

  The present invention relates to glucopyranosyloxybenzylbenzene derivatives represented by the general formula: wherein R 1 represents a hydrogen atom, a hydroxy group, a substituted or unsubstituted amino group, a carbamoyl group, a substituted or unsubstituted(lower alkyl) group, a substituted or unsubstituted(lower alkoxy) group etc.; R 2 represents a hydrogen atom or a lower alkyl group; and R 3 represents a substituted or unsubstituted(lower alkyl) group, a substituted or unsubstituted(lower alkoxy) group, a substituted or unsubstituted(lower alkylthio) group etc., or pharmaceutically acceptable salts thereof, which have an inhibitory activity in human SGLT2 and are useful as agents for the prevention or treatment of a disease associated with hyperglycemia such as diabetes, diabetic complication or obesity, pharmaceutical compositions comprising the same and intermediates thereof.

  本发明涉及一种由通式表示的葡萄糖吡喃氧基苯基苯乙烯衍生物： 其中，R1表示氢原子，羟基，取代或未取代的氨基，氨基甲酰基，取代或未取代的（较低烷基）基团，取代或未取代的（较低烷氧基）基团等；R2表示氢原子或较低烷基基团；R3表示取代或未取代的（较低烷基）基团，取代或未取代的（较低烷氧基）基团，取代或未取代的（较低烷硫基）基团等，或其药学上可接受的盐，其具有对人类SGLT2的抑制活性，可用作预防或治疗与高血糖相关的疾病，如糖尿病、糖尿病并发症或肥胖症的药物，以及包含它们的制药组合物和中间体。
• Glucopyranosyloxybenzyl benzene derivatives, medicinal compositions containing the same and intermediates in the production thereof
  申请人：——

  公开号：US20040063170A1

  公开（公告）日：2004-04-01

  The present invention relates to glucopyranosyloxybenzylbenzene derivatives represented by the general formula: 1 wherein R 1 represents a hydrogen atom, a hydroxy group, a substituted or unsubstituted amino group, a carbamoyl group, a substituted or unsubstituted (lower alkyl) group, a substituted or unsubstituted (lower alkoxy) group etc.; R 2 represents a hydrogen atom or a lower alkyl group; and R 3 represents a substituted or unsubstituted (lower alkyl) group, a substituted or unsubstituted (lower alkoxy) group, a substituted or unsubstituted (lower alkylthio) group etc., or pharmaceutically acceptable salts thereof, which have an inhibitory activity in human SGLT2 and are useful as agents for the prevention or treatment of a disease associated with hyperglycemia such as diabetes, diabetic complication or obesity, pharmaceutical compositions comprising the same and intermediates thereof.

  本发明涉及由下式表示的葡萄糖吡喃基氧基苯基苯基衍生物： 其中，R1代表氢原子、羟基、取代或未取代的氨基、氨基甲酰基、取代或未取代的(较低烷基)基团、取代或未取代的(较低烷氧基)基团等；R2代表氢原子或较低烷基基团；R3代表取代或未取代的(较低烷基)基团、取代或未取代的(较低烷氧基)基团、取代或未取代的(较低烷硫基)基团等，或其药学上可接受的盐，其在人类SGLT2中具有抑制活性，并且可用作预防或治疗与高血糖有关的疾病，如糖尿病、糖尿病并发症或肥胖症的药剂。本发明还涉及包含上述衍生物的制药组合物及其中间体。
• Novel Cyclohexane Derivative, Prodrug Thereof and Salt Thereof, and Therapeutic Agent Containing the Same for Diabetes
  申请人：Matsuoka Hiroharu

  公开号：US20080318874A1

  公开（公告）日：2008-12-25

  A cyclohexane derivative having the function of reducing a blood sugar level and having preferable properties required of medicines, such as long-lasting drug activity, metabolic stability, and safety; and a medicinal composition for use in the prevention or treatment of diseases attributable to hyperglycemia, such as diabetes, e.g., insulin dependent diabetes mellitus (type 1 diabetes) or noninsulin-dependent diabetes mellitus (type 2 diabetes), complications of diabetes, and obesity. The derivative is a compound represented by the formula (I): (wherein A is —O—, —CH 2 —, or —NH—; n is an integer selected between 0 and 1; R 6 and R 7 each independently is hydrogen or C 1-6 alkyl; m is an integer selected among 1-3; Q is selected among the following formulae Q 1 to Q 5 ; Ar 1 is optionally substituted arylene or optionally substituted heteroarylene, provided that the heteroarylene may be bonded to an aromatic carbocycle or aromatic heterocycle to form a fused ring; and Ar 2 is optionally substituted aryl or optionally substituted heteroaryl), a prodrug of the compound, or a pharmaceutically acceptable salt of either. Also provided are a medicine, a medicinal composition, or the like each containing the compound.

  一种环己烷衍生物，具有降低血糖水平的功能，并具有药物所需的优良特性，如持久的药物活性、代谢稳定性和安全性；以及用于预防或治疗与高血糖相关的疾病，如糖尿病，例如胰岛素依赖性糖尿病（1型糖尿病）或非胰岛素依赖性糖尿病（2型糖尿病），糖尿病并发症和肥胖症的药物组合物。该衍生物是由式（I）表示的化合物：（其中A是-O-、-CH2-或-NH-；n是在0和1之间选择的整数；R6和R7各自独立地是氢或C1-6烷基；m是在1-3之间选择的整数；Q在以下式Q1至Q5之间选择；Ar1是可选的取代芳基或可选的取代杂环芳基，但杂环芳基可以与芳香环或芳香杂环结合形成融合环；Ar2是可选的取代芳基或可选的取代杂环芳基），该化合物的前药物或任一药物学上可接受的盐。还提供了含有该化合物的药物、药物组合物等。
• Cyclohexane derivative, prodrug thereof and salt thereof, and therapeutic agent containing the same for diabetes
  申请人：Chugai Seiyaku Kabushiki Kaisha

  公开号：US08048897B2

  公开（公告）日：2011-11-01

  A cyclohexane derivative having the function of reducing a blood sugar level and having preferable properties required of medicines, such as long-lasting drug activity, metabolic stability, and safety; and a medicinal composition for use in the prevention or treatment of diseases attributable to hyperglycemia, such as diabetes, e.g., insulin dependent diabetes mellitus (type 1 diabetes) or noninsulin-dependent diabetes mellitus (type 2 diabetes), complications of diabetes, and obesity. The derivative is a compound represented by the formula (I): (wherein A is —O—, —CH2—, or —NH—; n is an integer selected between 0 and 1; R6 and R7 each independently is hydrogen or C1-6 alkyl; m is an integer selected among 1-3; Q is selected among the following formulae Q1 to Q5; Ar1 is optionally substituted arylene or optionally substituted heteroarylene, provided that the heteroarylene may be bonded to an aromatic carbocycle or aromatic heterocycle to form a fused ring; and Ar2 is optionally substituted aryl or optionally substituted heteroaryl), a prodrug of the compound, or a pharmaceutically acceptable salt of either. Also provided are a medicine, a medicinal composition, or the like each containing the compound.

  一种环己烷衍生物，具有降低血糖水平和药物所需的良好特性，如持久的药物活性，代谢稳定性和安全性；以及用于预防或治疗由高血糖引起的疾病，如糖尿病，例如胰岛素依赖性糖尿病（1型糖尿病）或非胰岛素依赖性糖尿病（2型糖尿病），糖尿病并发症和肥胖症的药物组合物。该衍生物是由式（I）表示的化合物：（其中A是—O—，—CH2—或—NH—；n是在0和1之间选定的整数；R6和R7各自独立地是氢或C1-6烷基；m是在1-3之间选定的整数；Q在以下公式Q1至Q5之间选定；Ar1是可选择取代的芳基或可选择取代的杂芳基，前提是杂芳基可以与芳香碳环或芳香杂环结合形成融合环；Ar2是可选择取代的芳基或可选择取代的杂芳基），该化合物的前药物或任一的药学上可接受的盐。还提供了一种药物，药物组合物或包含该化合物的类似物。
• GLUCOPYRANOSYLOXYBENZYL BENZENE DERIVATIVES, MEDICINAL COMPOSITIONS CONTAINING THE SAME AND INTERMEDIATES IN THE PRODUCTION THEREOF
  申请人：Kissei Pharmaceutical Co., Ltd.

  公开号：EP1344780A1

  公开（公告）日：2003-09-17

  The present invention relates to glucopyranosyloxybenzylbenzene derivatives represented by the general formula: wherein R1 represents a hydrogen atom, a hydroxy group, a substituted or unsubstituted amino group, a carbamoyl group, a substituted or unsubstituted(lower alkyl) group, a substituted or unsubstituted(lower alkoxy) group etc.; R2 represents a hydrogen atom or a lower alkyl group; and R3 represents a substituted or unsubstituted(lower alkyl) group, a substituted or unsubstituted(lower alkoxy) group, a substituted or unsubstituted (lower alkylthio) group etc., or pharmaceutically acceptable salts thereof, which have an inhibitory activity in human SGLT2 and are useful as agents for the prevention or treatment of a disease associated with hyperglycemia such as diabetes, diabetic complication or obesity, pharmaceutical compositions comprising the same and intermediates thereof.

  本发明涉及通式代表的葡糖基吡喃氧基苄基苯衍生物： 其中R1代表氢原子、羟基、取代或未取代的氨基、氨基甲酰基、取代或未取代的(低级烷基)基团、取代或未取代的(低级烷氧基)基团等；R2代表氢原子或低级烷基；R3代表取代或未取代的(低级烷基)基团、取代或未取代的(低级烷氧基)基团、取代或未取代的(低级烷硫基)基团等、或其药学上可接受的盐，它们对人类 SGLT2 具有抑制活性，可用作预防或治疗与高血糖有关的疾病（如糖尿病、糖尿病并发症或肥胖症）的制剂、包含这些制剂的药物组合物及其中间体。